Keros Therapeutics (KROS) Misses Q2 EPS by 5c

Keros Therapeutics (NASDAQ: KROS) reported Q2 EPS of ($1.45), $0.05 worse than the analyst estimate of ($1.40).

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• William Blair Reiterates Outperform Rating on SpaceX (SPCX)
• Glucotrack secures $11.5M in convertible note financing